{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:20:19Z","timestamp":1784262019003,"version":"3.55.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01498","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T05:08:54Z","timestamp":1547010534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective"],"prefix":"10.3389","volume":"9","author":[{"given":"Matti","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashyap","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Luiz H.","family":"Arantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.","volume":"29","author":"Aapro","year":"","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40259-018-0262-9","article-title":"Epoetin biosimilars in the treatment of chemotherapy-induced anemia: 10 years\u2019 experience gained.","volume":"32","author":"Aapro","year":"","journal-title":"BioDrugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1758834012444499","article-title":"Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer.","volume":"4","author":"Aapro","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2217\/fon.14.43","article-title":"Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.","volume":"10","author":"Abraham","year":"2014","journal-title":"Future Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1056\/NEJMoa040528","article-title":"Pure red-cell aplasia and epoetin therapy.","volume":"351","author":"Bennett","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B6","first-page":"260","article-title":"Reassessments of ESAs for cancer treatment in the US and Europe.","volume":"24","author":"Bennett","year":"2010","journal-title":"Oncology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.","volume":"339","author":"Besarab","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B8","first-page":"469","article-title":"The economics of biosimilars.","volume":"6","author":"Blackstone","year":"2013","journal-title":"Am. Health Drug Benefits"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003407.pub2","article-title":"Erythropoietin for patients with malignant disease.","author":"Bohlius","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer\u2013meta-analysis based on individual patient data.","author":"Bohlius","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.ejca.2004.07.015","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.","volume":"40","author":"Bokemeyer","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011619","article-title":"Erythropoietin.","volume":"3","author":"Bunn","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1523-5394.1999.74008.x","article-title":"The effect of epoetin alfa on quality of life in anemic cancer patients.","volume":"7","author":"Cella","year":"1999","journal-title":"Cancer Pract."},{"key":"B15","year":"2007","journal-title":"National Coverage Determination (NCD) for Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions (110.21)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Drueke","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.exphem.2008.08.003","article-title":"Erythropoietins: a common mechanism of action.","volume":"36","author":"Elliott","year":"2008","journal-title":"Exp. Hematol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V8.4.349.349","article-title":"Humoral regulation of red cell production.","volume":"8","author":"Erslev","year":"1953","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.1990.03440060071035","article-title":"The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.","volume":"263","author":"Evans","year":"1990","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/bjc.2011.395","article-title":"Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation.","volume":"105","author":"Fujisaka","year":"2011","journal-title":"Br. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JOP.0863501","article-title":"Continued regulatory actions affecting the use of erythropoiesis-stimulating agents.","volume":"4","author":"Hagerty","year":"2008","journal-title":"J. Oncol. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cncr.23280","article-title":"Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/179633a0","article-title":"Role of the kidney in erythropoiesis.","volume":"179","author":"Jacobson","year":"1957","journal-title":"Nature"},{"key":"B25","year":"2012","journal-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease."},{"key":"B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clinthera.2015.11.018","article-title":"Cardiovascular morbidity and pure red cell aplasia associated with epoetin theta therapy in patients with chronic kidney disease: a prospective, noninterventional, multicenter cohort study.","volume":"38","author":"Lammerich","year":"2016","journal-title":"Clin. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/ph7090943","article-title":"Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets.","volume":"7","author":"Lammers","year":"2014","journal-title":"Pharmaceuticals"},{"key":"B29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly.","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1200\/JCO.2015.63.5649","article-title":"A randomized, open-label, multicenter, phase iii study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy.","volume":"34","author":"Leyland-Jones","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1093\/ndt\/gfq336","article-title":"Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study.","volume":"25","author":"Locatelli","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"B33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/iub.322","article-title":"From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones.","volume":"62","author":"Lodish","year":"2010","journal-title":"IUBMB Life"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"B35","author":"Luksenberg","year":"2004","journal-title":"Safety Concerns Associated with Aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy."},{"key":"B36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1046\/j.1525-139x.2000.00036.x","article-title":"Hematocrit level and associated mortality in hemodialysis patients.","volume":"10","author":"Ma","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ndt\/gfu297","article-title":"Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).","volume":"30","author":"Macdougall","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","article-title":"Epoetin-associated pure red cell aplasia: past, present, and future considerations.","volume":"48","author":"McKoy","year":"2008","journal-title":"Transfusion"},{"key":"B39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000438976","article-title":"Biosimilar epoetin zeta in oncology and haematology: development and experience following 6 years of use.","volume":"135","author":"Michallet","year":"2016","journal-title":"Acta Haematol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease.","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/jnci\/djt145","article-title":"Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.","volume":"105","author":"Moebus","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"B42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3892\/mco.2015.693","article-title":"Lessons from the past: long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.","volume":"4","author":"Mountzios","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.325","article-title":"A double-blind, randomized, placebo-controlled phase 3 noninferiority study of darbepoetin alfa for anemia in advanced NSCLC","author":"Nagarkar","year":"2018","journal-title":"Proceedings of the IASLC 19th World Conference on Lung Cancer; Sept 23\u201326"},{"key":"B44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3816\/CLC.2011.n.009","article-title":"Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.","volume":"12","author":"Nagel","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1172\/JCI105089","article-title":"Erythropoiesis in anephric man.","volume":"43","author":"Nathan","year":"1964","journal-title":"J. Clin. Invest."},{"key":"B46","volume":"30","year":"2018","journal-title":"Cancer- and Chemotherapy-Induced Anemia (Version 3.2018)."},{"key":"B47","year":"2015","journal-title":"NICE Guideline (NG-8): Chronic Kidney Disease: Managing Anemia."},{"key":"B48","first-page":"S192","article-title":"NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative.","volume":"30","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdt505","article-title":"Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.","volume":"25","author":"Nitz","year":"2014","journal-title":"Ann. Oncol."},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1276.1276","article-title":"The reduction of erythropoietin stimulating agent (ESA) use due to the FDA black box warning.","volume":"124","author":"Noxon","year":"2014","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2004121039","article-title":"Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.","volume":"16","author":"Parfrey","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","article-title":"Practical management of iron overload.","volume":"115","author":"Porter","year":"2001","journal-title":"Br. J. Haematol."},{"key":"B54","volume":"26","year":"2017","journal-title":"The Impact of Biosimilar Competition in Europe."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2002-06-1767","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.","volume":"100","author":"Rizzo","year":"2002","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2007-08-109488","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update.","volume":"111","author":"Rizzo","year":"2008","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"434","DOI":"10.6004\/jnccn.2012.0044","article-title":"A perspective on the evolution of management of cancer- and chemotherapy-induced anemia.","volume":"10","author":"Rodgers","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B59","doi-asserted-by":"publisher","first-page":"v244","DOI":"10.1093\/annonc\/mdq202","article-title":"Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use.","volume":"21","author":"Schrijvers","year":"2010","journal-title":"Ann. Oncol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.614","author":"Seetasith","year":"2013","journal-title":"Impacts of Black Box Warning, National Coverage Determination, and Risk Evaluation and Mitigation Strategies on The Inpatient On-Label and Off-Label Use of Erythropoiesis-Stimulating Agents."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B62","first-page":"s331","article-title":"The economic implications of biosimilars.","volume":"21","author":"Singh","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"B63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/19420862.2015.1008346","article-title":"Clinical considerations for the development of biosimilars in oncology.","volume":"7","author":"Socinski","year":"2015","journal-title":"MAbs"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States.","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/annonc\/mdq713","article-title":"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2013outcome on prognosis.","volume":"22","author":"Untch","year":"2011","journal-title":"Ann. Oncol."},{"key":"B67","year":"","journal-title":"FDA Advisory Committee Briefing Document. Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety Risk Management Committee."},{"key":"B68","year":"","journal-title":"FDA Alert. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (Darbepoetin), Epogen (Epoetin Alfa), and Procrit (Epoetin Alfa)]."},{"key":"B69","year":"2011","journal-title":"FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease."},{"key":"B70","year":"2017","journal-title":"Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin Alfa (marketed as Procrit, Epogen), Darbepoetin Alfa (marketed as Aranesp)."},{"key":"B71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CLEP.S89480","article-title":"Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010\u20132013.","volume":"8","author":"Xu","year":"2016","journal-title":"Clin. Epidemiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T21:18:50Z","timestamp":1573679930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":71,"alternative-id":["10.3389\/fphar.2018.01498"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01498","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"article-number":"1498"}}